<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PENTASA - mesalamine capsule </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>PENTASA®(mesalamine)Controlled-Release Capsules 250 mg and 500 mgPrescribing Information as of April 2012Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<a href="http://"></a><p class="First"></p>
<p>PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an aminosalicylate anti-inflammatory agent for gastrointestinal use. </p>
<p>Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid. It has a molecular weight of 153.14.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178&amp;name=MM1.jpg"></div>
<p></p>
<p>Each 250 mg capsule contains 250 mg of mesalamine. It also contains the following inactive ingredients: acetylated monoglyceride, castor oil, colloidal silicon dioxide, ethylcellulose, hydroxypropyl methylcellulose, starch, stearic acid, sugar, talc, and white wax. The capsule shell contains D&amp;C Yellow #10, FD&amp;C Blue #1, FD&amp;C Green #3, gelatin, titanium dioxide, and other ingredients.</p>
<p>Each 500 mg capsule contains 500 mg of mesalamine. It also contains the following inactive ingredients: acetylated monoglyceride, castor oil, colloidal silicon dioxide, ethylcellulose, hydroxypropyl methylcellulose, starch, stearic acid, sugar, talc, and white wax. The capsule shell contains FD&amp;C Blue #1, gelatin, titanium dioxide, and other ingredients.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<p>Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component is therapeutically active in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. The usual oral dose of sulfasalazine for active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> in adults is 2 to 4 g per day in divided doses. Four grams of sulfasalazine provide 1.6 g of free mesalamine to the colon.</p>
<p>The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, ie, prostanoids, and through the lipoxygenase pathways, ie, leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs), is increased in patients with chronic <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, and it is possible that mesalamine diminishes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.</p>
<p><span class="Bold"><span class="Underline">Human Pharmacokinetics and Metabolism<br></span></span><span class="Bold">Absorption. </span>PENTASA is an ethylcellulose-coated, controlled-release formulation of mesalamine designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. Based on urinary excretion data, 20% to 30% of the mesalamine in PENTASA is absorbed. In contrast, when mesalamine is administered orally as an unformulated 1-g aqueous suspension, mesalamine is approximately 80% absorbed.</p>
<p>Plasma mesalamine concentration peaked at approximately 1 μg/mL 3 hours following a 1-g PENTASA dose and declined in a biphasic manner. The literature describes a mean terminal half-life of 42 minutes for mesalamine following intravenous administration. Because of the continuous release and absorption of mesalamine from PENTASA throughout the gastrointestinal tract, the true elimination half-life cannot be determined after oral administration. N-acetylmesalamine, the major metabolite of mesalamine, peaked at approximately 3 hours at 1.8 μg/mL, and its concentration followed a biphasic decline. Pharmacological activities of N-acetylmesalamine are unknown, and other metabolites have not been identified. </p>
<p>Oral mesalamine pharmacokinetics were nonlinear when PENTASA capsules were dosed from 250 mg to 1 g four times daily, with steady-state mesalamine plasma concentrations increasing about nine times, from 0.14 μg/mL to 1.21 μg/mL, suggesting saturable first-pass metabolism. N-acetylmesalamine pharmacokinetics were linear.</p>
<p><span class="Bold">Elimination.</span> About 130 mg free mesalamine was recovered in the feces following a single 1-g PENTASA dose, which was comparable to the 140 mg of mesalamine recovered from the molar equivalent sulfasalazine tablet dose of 2.5 g. Elimination of free mesalamine and salicylates in feces increased proportionately with PENTASA dose. N-acetylmesalamine was the primary compound excreted in the urine (19% to 30%) following PENTASA dosing.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<a href="http://"></a><p class="First"></p>
<p>In two randomized, double-blind, placebo-controlled, dose-response trials (UC-1 and UC-2) of 625 patients with active mild to moderate <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, PENTASA, at an oral dose of 4 g/day given 1 g four times daily, produced consistent improvement in prospectively identified primary efficacy parameters, PGA, Tx F, and SI as shown in the table below.</p>
<p>The 4-g dose of PENTASA also gave consistent improvement in secondary efficacy parameters, namely the frequency of trips to the toilet, stool consistency, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, abdominal/<span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">rectal pain</span>, and urgency. The 4-g dose of PENTASA induced remission as assessed by endoscopic and symptomatic endpoints. </p>
<p>In some patients, the 2-g dose of PENTASA was observed to improve efficacy parameters measured. However, the 2-g dose gave inconsistent results in primary efficacy parameters across the two adequate and well-controlled trials.</p>
<table>
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<tbody class="Headless">
<tr class="First">
<td> <br><br>Parameter Evaluated </td>
<td> <span class="Bold">Clinical Trial UC-1</span>
</td>
<td> <span class="Bold">Clinical Trial-UC-2</span>
</td>
</tr>
<tr>
<td> <br>PL<br>(n=90) </td>
<td>  PENTASA </td>
<td> <br>PL<br>(n=83) </td>
<td>  PENTASA </td>
</tr>
<tr>
<td>  4 g/day<br>(n=95) </td>
<td>  2 g/day<br>(n=97) </td>
<td>  4 g/day<br>(n=85) </td>
<td>  2 g/day<br>(n=83) </td>
</tr>
<tr>
<td>  PGA </td>
<td>  36% </td>
<td>  59%* </td>
<td>  57%* </td>
<td>  31% </td>
<td>  55%* </td>
<td>  41% </td>
</tr>
<tr>
<td>  Tx F </td>
<td>  22% </td>
<td>  9%* </td>
<td>  18% </td>
<td>  31% </td>
<td>  9%* </td>
<td>  17%* </td>
</tr>
<tr>
<td>  SI </td>
<td>-2.5 </td>
<td>  -5.0* </td>
<td>  -4.3* </td>
<td>  -1.6 </td>
<td>  -3.8* </td>
<td>  -2.6 </td>
</tr>
<tr>
<td>  Remission<span class="Sup">+</span>
</td>
<td>  12% </td>
<td>  26%* </td>
<td>  24%* </td>
<td>  12% </td>
<td>  27%* </td>
<td>  12% </td>
</tr>
<tr class="Last"><td>  * p&lt;0.05 vs placebo.<br><br>PGA: Physician Global Assessment: proportion of patients with complete or marked improvement.<br><br>Tx F:Treatment Failure: proportion of patients developing severe or fulminant UC requiring steroid therapy or hospitalization or worsening of the disease at 7 days of therapy, or lack of significant improvement by 14 days of therapy.<br><br>SI: Sigmoidoscopic Index: an objective measure of disease activity rated by a standard (15-point) scale that includes mucosal vascular pattern, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, friability, granularity/ulcerations, and mucopus: improvement over baseline.<br><br><span class="Sup">+</span> Defined as complete resolution of symptoms plus improvement of endoscopic endpoints. To be considered in remission, patients had a "1" score for one of the endoscopic components (mucosal vascular pattern, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, granularity, or friability) and "0" for the others. </td></tr>
</tbody>
</table>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>PENTASA is contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mesalamine, any other components of this medication, or salicylates.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>Caution should be exercised if PENTASA is administered to patients with impaired hepatic function.</p>
<p>Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>. Although the exact frequency of occurrence cannot be ascertained, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, sometimes <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. If acute intolerance syndrome is suspected, prompt withdrawal is required. If a rechallenge is performed later in order to validate the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, it should be carried out under close medical supervision at reduced dose and only if clearly needed.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Caution should be exercised if PENTASA is administered to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Single reports of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> associated with mesalamine therapy have been described in the foreign literature. There have been rare reports of interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> in patients receiving PENTASA. In animal studies, a 13-week oral toxicity study in mice and 13-week and 52-week oral toxicity studies in rats and cynomolgus monkeys have shown the kidney to be the major target organ of mesalamine toxicity. Oral daily doses of 2400 mg/kg in mice and 1150 mg/kg in rats produced renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, <span class="product-label-link" type="condition" conceptid="194994" conceptname="Renal infarction">renal infarct</span>, papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">tubular necrosis</span>, and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>. In cynomolgus monkeys, oral daily doses of 250 mg/kg or higher produced <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, papillary <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Patients with preexisting <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, increased BUN or serum creatinine, or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> should be carefully monitored, especially during the initial phase of treatment. Mesalamine-induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> should be suspected in patients developing renal dysfunction during treatment.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>There are no data on interactions between PENTASA and other drugs.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>In a 104-week dietary carcinogenicity study of mesalamine, CD-1 mice were treated with doses up to 2500 mg/kg/day and it was not tumorigenic. For a 50 kg person of average height (1.46 m<span class="Sup">2</span> body surface area), this represents 2.5 times the recommended human dose on a body surface area basis (2960 mg/m<span class="Sup">2</span>/day). In a 104-week dietary carcinogenicity study in Wistar rats, mesalamine up to a dose of 800 mg/kg/day was not tumorigenic. This dose represents 1.5 times the recommended human dose on a body surface area basis.</p>
<p>No evidence of mutagenicity was observed in an in vitro Ames test and in an in vivo mouse micronucleus test.</p>
<p>No effects on fertility or reproductive performance were observed in male or female rats at oral doses of mesalamine up to 400 mg/kg/day (0.8 times the recommended human dose based on body surface area).</p>
<p>Semen abnormalities and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> in men, which have been reported in association with sulfasalazine, have not been seen with PENTASA capsules during controlled clinical trials.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7"></a><p></p>
<h1>PREGNANCY</h1>
<a href="http://"></a><p class="First"></p>
<p>Category B. Reproduction studies have been performed in rats at doses up to 1000 mg/kg/day (5900 mg/M<span class="Sup">2</span>) and rabbits at doses of 800 mg/kg/day (6856 mg/M<span class="Sup">2</span>) and have revealed no evidence of teratogenic effects or harm to the fetus due to mesalamine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, PENTASA should be used during pregnancy only if clearly needed.</p>
<p>Mesalamine is known to cross the placental barrier.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Minute quantities of mesalamine were distributed to breast milk and amniotic fluid of pregnant women following sulfasalazine therapy. When treated with sulfasalazine at a dose equivalent to 1.25 g/day of mesalamine, 0.02 μg/mL to 0.08 μg/mL and trace amounts of mesalamine were measured in amniotic fluid and breast milk, respectively. N-acetylmesalamine, in quantities of 0.07 μg/mL to 0.77 μg/mL and 1.13 μg/mL to 3.44 μg/mL, was identified in the same fluids, respectively. </p>
<p>Caution should be exercised when PENTASA is administered to a nursing woman.</p>
<p>No controlled studies with PENTASA during breast-feeding have been carried out. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> like <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the infant cannot be excluded. </p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Safety and efficacy of PENTASA in pediatric patients have not been established.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>In combined domestic and foreign clinical trials, more than 2100 patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn's disease received PENTASA therapy. Generally, PENTASA therapy was well tolerated. The most common events (ie, greater than or equal to 1%) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3.4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.0%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.8%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.7%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1.6%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.5%), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.0%).</p>
<p>In two domestic placebo-controlled trials involving over 600 <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients, adverse events were fewer in PENTASA<span class="Sup">®</span> (mesalamine)-treated patients than in the placebo group (PENTASA 14% vs placebo 18%) and were not dose-related. Events occurring at 1% or more are shown in the table below. Of these, only <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were more frequent in the PENTASA group. Withdrawal from therapy due to adverse events was more common on placebo than PENTASA (7% vs 4%).</p>
<table>
<col span="1">
<col span="1">
<col span="1">
<tbody class="Headless">
<tr class="First"><th colspan="3"><span class="Bold">Table 1. Adverse Events Occurring in More than 1% of Either Placebo or PENTASA Patients in Domestic Placebo-controlled <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span> Trials. (PENTASA Comparison to Placebo)</span></th></tr>
<tr>
<td> <br>Event </td>
<td>  PENTASA<br>n=451 </td>
<td>  Placebo<br>n=173 </td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br><span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">Melena</span> (<span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">Bloody Diarrhea</span>)<br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>Rectal Urgency<br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>Worsening of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative Colitis</span><br><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> </td>
<td> 16 (3.5%)<br>10 (2.2%)<br>14 (3.1%)<br>5 (1.1%)<br>4 (0.9%)<br>6 (1.3%)<br>5 (1.1%)<br>4 (0.9%)<br>1 (0.2%)<br>5 (1.1%)<br>2 (0.4%)<br>1 (0.2%) </td>
<td>  13 (7.5%)<br>6 (3.5%)<br>-----<br>7 (4.0%)<br>6 (3.5%)<br>2 (1.2%)<br>2 (1.2%)<br>2 (1.2%)<br>4 (2.3%)<br>-----<br>2 (1.2%)<br>2 (1.2%) </td>
</tr>
</tbody>
</table>
<p>Clinical laboratory measurements showed no significant abnormal trends for any test, including measurement of hematological, liver, and kidney function.</p>
<p>The following adverse events, presented by body system, were reported infrequently (ie, less than 1%) during domestic <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and Crohn's disease trials. In many cases, the relationship to PENTASA has not been established.</p>
<p><span class="Bold">Gastrointestinal: </span>abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcer</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">GGTP increase</span>, GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, increased alkaline phosphatase, LDH increase, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcer</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increase, SGPT increase, stool abnormalities (color or texture change), <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span></p>
<p><span class="Bold">Dermatological: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, vasodilation</p>
<p><span class="Bold">Other: </span><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, amylase increase, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4275882" conceptname="Hypomenorrhea">hypomenorrhea</span>, Kawasaki-like syndrome, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, lipase increase, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></p>
<p>One week after completion of an 8-week <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> study, a 72-year-old male, with no previous history of pulmonary problems, developed <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. The patient was subsequently diagnosed with <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pulmonary fibrosis</span> without <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> by one physician and <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span> with organizing <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> by a second physician. A causal relationship between this event and mesalamine therapy has not been established.</p>
<p>Published case reports and/or spontaneous postmarketing surveillance have described infrequent instances of <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, fatal <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and T-wave abnormalities, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> while receiving mesalamine therapy. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> can be a part of the clinical presentation of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, which could involve <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, can be seen in connection with PENTASA therapy.</p>
<p><span class="Bold"><span class="Underline">Postmarketing Reports<br></span></span>The following events have been identified during post-approval use of the PENTASA brand of mesalamine in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to mesalamine:</p>
<p><span class="Bold">Gastrointestinal: </span>Reports of hepatotoxicity, including elevated liver enzymes (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, cirrhosis, and possible <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span> including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these cases were fatal. One case of Kawasaki-like syndrome which included hepatic function changes was also reported. </p>
<p><span class="Bold">Other: </span>Postmarketing reports of <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been received in patients taking PENTASA. </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>Single oral doses of mesalamine up to 5 g/kg in pigs or a single intravenous dose of mesalamine at 920 mg/kg in rats were not lethal.</p>
<p>There is no clinical experience with PENTASA overdosage. PENTASA is an aminosalicylate, and symptoms of salicylate toxicity may be possible, such as: <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with salicylates can lead to disruption of electrolyte balance and blood-pH, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.</p>
<p><span class="Bold">Treatment of Overdosage. </span>Since PENTASA is an aminosalicylate, conventional therapy for salicylate toxicity may be beneficial in the event of acute overdosage. This includes prevention of further gastrointestinal tract absorption by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and, if necessary, by gastric lavage. Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be corrected by the administration of appropriate intravenous therapy. Adequate renal function should be maintained.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<a href="http://"></a><p class="First"></p>
<p>The recommended dosage for the induction of remission and the symptomatic treatment of mildly to moderately active <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> is 1g (4 PENTASA 250 mg capsules or 2 PENTASA 500 mg capsules) 4 times a day for a total daily dosage of 4g. Treatment duration in controlled trials was up to 8 weeks.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a href="http://"></a><p class="First"></p>
<p>PENTASA controlled-release 250 mg capsules are supplied in bottles of 240 capsules (NDC 54092-189-81). Each green and blue capsule contains 250 mg of mesalamine in controlled-release beads. PENTASA controlled-release capsules are identified with a pentagonal starburst logo and the number 2010 on the green portion and PENTASA 250 mg or S429 250 mg on the blue portion of the capsules.</p>
<p>PENTASA controlled-release 500 mg capsules are supplied in bottles of 120 capsules (NDC 54092-191-12). Each blue capsule contains 500 mg of mesalamine in controlled-release beads. PENTASA controlled-release capsules are identified with a pentagonal starburst logo and PENTASA 500 mg or S429 500 mg on the capsules.</p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. </p>
<p>Manufactured for <span class="Bold">Shire US Inc</span>.<br>725 Chesterbrook Blvd., Wayne, PA 19087, USA<br>PENTASA is a registered trademark of Ferring B.V.<br>© 2012 Shire US Inc.</p>
<p>Rev. 4/2012</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
    DRUG: Pentasa <br>GENERIC: mesalamine<br>DOSAGE: CAPSULE<br>ADMINSTRATION: ORAL<br>NDC: 49349-561-02<br>STRENGTH:500 mg<br>COLOR: blue<br>SHAPE: CAPSULE<br>SCORE: No score<br>SIZE: 23 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178&amp;name=MM2.jpg"></div>
<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bdf3222-469c-44b0-bbcd-25faeaeff178&amp;name=MM3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PENTASA 		
					</strong><br><span class="contentTableReg">mesalamine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-561(NDC:54092-191)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MESALAMINE</strong> (MESALAMINE) </td>
<td class="formItem">MESALAMINE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CASTOR OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PENTASA;500;mg;S429;500;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-561-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020049</td>
<td class="formItem">03/19/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2d9e356c-041b-4e3f-9b11-551da2ddc31a</div>
<div>Set id: 1bdf3222-469c-44b0-bbcd-25faeaeff178</div>
<div>Version: 1</div>
<div>Effective Time: 20130319</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
